Published in final edited form as:

Toxicon. 2008 July ; 52(1): 186–189. doi:10.1016/j.toxicon.2008.04.163.

Neutralization of Lethality and Proteolytic Activities of Malayan Pit Viper (*Calloselasma rhodostoma*) Venom with North American Virginia Opossum (*Didelphis virginiana*) Serum

Piboon Pornmanee^a, Elda E. Sánchez^b, Gonzalo López^b, Amorn Petsom^c, Orawan Khaw^d, Narumol Pakmanee^d, Lawan Chanhom^d, Polkit Sangvanich^c, and John C. Pérez^{b,*}

^aProgram of Biotechnology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand ^bNatural Toxins Research Center, Texas A&M University-Kingsville, MSC 158, Kingsville, TX 78363, USA ^cThe Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, Bangkok 10330, Thailand ^dQueen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, 10330, Thailand

Abstract

Malayan pit viper (*Calloselasma rhodostoma*) envenomation is a major health problem in South East Asia. During envenomation, venom components mainly affect the hemostatic system. The sera from the North American Virginia opossums (*Didelphis virginiana*) were able to neutralize the venom of the Malayan pit viper. These natural inhibitors could be explored as potential therapeutics against envenomations of a variety of venomous snake species in different geographical habitats.

Keywords

snake; venom; Malayan pit viper; *Calloselasma rhodostoma*; Virginia opossum; *Didelphis virginiana*; antifibrinolytic; antihemorrhagic; antigelatinase; LD₅₀; ED₅₀

The Malayan pit viper (*Calloselasma rhodostoma*) is a common snake found in most parts of South East Asia (Daltrey et al., 1996). Its habitats include rubber and palm plantations, farms, rural villages, and rain forests. Snake envenomation is a serious medical problem in Thailand, especially in the agricultural areas where snakes are abundant (Pithayanukul et al., 2004). In 1992, a national survey of snakebites in Thailand showed that 70% of reported cases were caused by venomous snake species. The top four most common species responsible for snakebites in Thailand are *C. rhodostoma* (38%), *Trimeresurus albolabris* (27%), *Daboia russeli siamensis* (14%), *Naja atra* (10 %), and others (11%) (Viravan et al., 1992). Malayan pit viper venom affects the hemostatic system causing hemorrhage (Lu et al., 2005; Marsh & Williams, 2005; Pithayanukul et al., 2004), and myonecrosis (Tan et al., 1986).

© 2008 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1-361-593-3805; fax: +1-361-593-3798, kfjcp00@tamuk.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The Virginia opossum (*Didelphis virginiana*) is a marsupial animal living in Central and North America. Opossums show no signs of edema, ecchymosis, or necrosis when bitten by venomous snakes. These animals are naturally resistant to the proteolytic effects of Crotalid venoms (Pérez et al., 1978, 1979; Rodríguez-Acosta et al., 1995; Galán et al., 2004). They have metalloproteinase inhibitors in their sera that neutralize the hemorrhagic and other proteolytic activities caused by many snake venoms (Catanese & Kress, 1992; Domont et al., 1991; Jurgilas et al., 2003; McKeller and Pérez, 2002; Pérez et al., 1979; Sánchez et al., 1998). In light of these past discoveries, opossum sera were selected to test against Malayan pit viper venom.

The purpose of this research was to determine the inhibitory effects of *D. virginiana* sera on *C. rhodostoma* venom by utilizing a series of antiproteolytic assays and lethal doses. The toxicity of *C. rhodostoma* venom including lethal dose (LD₅₀) and proteolytic activities were also determined and compared with the activity of other North American snake venoms.

To date, there are no reports of any animal species in South East Asia having a natural resistance to the proteolytic activities of Malayan pit viper venom. The *D. virginiana* is the first marsupial species with antiproteolytic activity against Malayan pit viper venom. By nature, opossums and Malayan pit vipers exist in very distinct geographical locations; and therefore, opossums have never come in contact with Malayan pit vipers. Thus, it is assumed that the antiproteolytic activities observed in this study are not related to antibody neutralization. The neutralization is probably due to metalloproteinase similar to the results reported on the American continent (Menchaca and Pérez, 1981; Perales et al., 1986; Pérez and Sánchez, 1999; Perales et al., 2005). According to a previous report, there was no evidence to support that opossums produce antibodies against venom molecules when immunized (McKeller and Pérez, 2002). Opossum serum contains metalloproteinase inhibitors which neutralize toxins from Crotalid venoms (Menchaca and Pérez, 1981; Perales et al., 1986; Perales et al., 2005).

Crude *C. rhodostoma* venom had fibrinolytic, hemorrhagic, and gelatinase activities (Figs. 1, Table 1). Minimal fibrinolytic dose (MFD) of the venom was tested by a method of Bajwa et al. (1980) resulting with a MFD of 13 µg (Fig. 1A). The minimal hemorrhagic dose (MHD) of the venom, assayed by a method described by Omori-Satoh et al. (1972), resulted in a MHD of 15 µg (Fig. 1C) and the minimal gelatinase dose (MGD), followed by a method of Huang and Pérez (1980), was 10 µg (Fig. 1E). A total of 0.175, 0.43 and 0.022 mg of *D. virginiana* sera completely inhibited one MFD, MHD and MGD, respectively (Figs. 1B, 1D and 1F; Table 1). The inhibition ratios of *D. virginiana* serum against *C. rhodostoma* venom are shown in table 1. The most potent antiproteolytic activity was gelatinase (2.2:1). The antifibrinolytic and antihemorrhagic ratios were 13.5:1 and 29.2:1, respectively.

The LD₅₀ and the ED₅₀ for the venom and the sera, respectively, were calculated using the Spearman-Kärber (1978) method. The LD₅₀ for *C. rhodostoma* crude venom was 6.1 mg/kg body weight (Table 1). *Didelphis virginiana* serum was used to neutralize the 3 LD₅₀ of Malayan pit viper venom, with an ED₅₀ of 546 mg/kg. The LD₅₀ of Malayan pit viper venom was similar to those of Western Diamondback rattlesnake (5.10 mg/kg), Mojave rattlesnake Type B (5.10 mg/kg), the Southern copperhead (5.20 mg/kg), and Broad-banded Copperhead (6.80 mg/kg) (Sánchez et al., 2003). The most lethal venom indicated by LD₅₀ value was from Mojave rattlesnake Type A (0.47 mg/kg), which was 12.97 times more toxic than Malayan pit viper venom. The MHD of Malayan pit viper venom (15 µg) was similar to those of Mojave rattlesnake Type B (12.2 µg) and Blacktailed rattlesnake (12.5 µg). The most hemorrhagic venom was from the Eastern Diamondback rattlesnake (0.3 µg), which was 50 times more hemorrhagic than that of the Malayan pit viper (Sánchez et al., 2003).

From those comparisons, it can be concluded that most of North American snake species contain venom that is more potent than the venom in the Malayan pit vipers found in Thailand. On the other hand, the ED₅₀ for the opossum sera was rather high compared to that of commercial antivenoms (Consroe et al., 1995; Sánchez et al., 2003). Unlike commercial antivenoms, which have been purified, the opossum sera contains many other non-neutralizing molecules, and it is likely that the ED₅₀ will improve when the sera is purified.

This report provides supporting evidence of previous studies regarding opossums being resistant to snake venom. Opossum sera were capable of neutralizing metalloproteinases from Malayan pit viper venom including hemorrhagins, fibrinogenases, and gelatinases. Metalloproteinase inhibitors in opossum sera that are active against venom found in such a geographical diverse species of snake, raises a potential application for opossum sera to be used universally for treatment of envenomations. All venom molecules may not be equally important to neutralize and the hemorrhagins may be some of the most important to be neutralized. Hemorrhagins diffuse into the tissue, absorb on to vessels, and cause degradation of extracellular matrix and vascular basement membrane. The destruction of the vascular system can have a secondary effect of a quick release of other toxins (thrombin-like enzymes and procoagulants) into the circulation, which could cause coagulopathy problems. Anai et al. (2002) reported that JF-1 hemorrhagins from *B. jararaca* venom played an important role in the development of coagulopathy by causing rapid spreading of thrombin-like enzymes into the circulation. Studies show that metalloproteinases from snake venom (BaPI from *Bothrops asper* venom) have been neutralized by the synthetic inhibitor batimastat (Escalante et al., 2000). Furthermore, batimastat was able to reduce the local tissue damage induced by whole venom of *B. asper* (Rucavado et al., 2000). However, more studies should be considered to evaluate antivenom efficiency of opossum sera against a variety of snake venoms found in various parts of the world.

Acknowledgments

This research was supported in part by the Natural Toxins Research Center (NTRC), Texas A&M University-Kingsville: NIH/NCRR #1 P40 RR018300-01, NIH/RIMI #5 PMD000216-02, and NIH/SCORE #5 S06 GM008107-29. We are grateful to Nora Diaz De Leon, NTRC administrative officer for technical assistance, Mark Hockmuller and Lucy Arispe, and we gratefully acknowledge all of the NTRC staff. Thanks to Thai Red Cross Society for their venom and special thanks to the graduate school, Chulalongkorn University.

References

- Anai K, Sugiki M, Yoshida E, Maruyama M. Neutralization of a snake venom hemorrhagic metalloproteinase prevents coagulopathy after subcutaneous injection of *Bothrops jararaca* venom in rats. *Toxicon*. 2002; 40:63–68. [PubMed: 11602280]
- Bajwa SS, Markland FS, Russell FE. Fibrinolytic enzyme(s) in western diamondback rattlesnake (*Crotalus atrox*) venom. *Toxicon*. 1980; 18:285–290. [PubMed: 7394818]
- Catanese JJ, Kress LF. Isolation from opossum serum of a metalloproteinase inhibitor homologous to human alpha 1B-glycoprotein. *Biochemistry*. 1992; 31:410–418. [PubMed: 1731898]
- Consroe P, Egen NB, Russell FE, Gerrish DC, Smith A, Sidki A, Landon JT. Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice. *Am J Trop Med Hyg*. 1995; 53:507–510. [PubMed: 7485708]
- Domont GB, Perales J, Moussatche H. Natural anti-snake venom proteins. *Toxicon*. 1991; 29:1183–1194. [PubMed: 1801313]
- Escalante T, Franceschi A, Rucavado A, Gutiérrez JM. Effectiveness of Batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local tissue damage induced by BaPI, a

- hemorrhagic metalloproteinase from the venom of the snake *Bothrops asper*. *Biochem Pharmacol*. 2000; 60:269–274. [PubMed: 10825472]
- Galán JA, Sánchez EE, Rodríguez-Acosta A, Pérez JC. Neutralization of venoms from two Southern Pacific Rattlesnakes (*Crotalus helleri*) with commercial antivenoms and endothermic animal sera. *Toxicon*. 2004; 43:791–799. [PubMed: 15284013]
- Huang SY, Perez JC. Comparative study on hemorrhagic and proteolytic activities of snake venoms. *Toxicon*. 1980; 18:421–6. [PubMed: 7010684]
- Jurgilas PB, Neves-Ferreira AG, Domont GB, Perales J. PO41, a snake venom metalloproteinase inhibitor isolated from Philander opossum serum. *Toxicon*. 2003; 42:621–628. [PubMed: 14602117]
- Lu Q, Clemetson JM, Clemetson KJ. Snake venoms and hemostasis. *J Thromb Haemost*. 2005; 3:1791–1799. [PubMed: 16102046]
- Marsh N, Williams V. Practical applications of snake venom toxins in haemostasis. *Toxicon*. 2005; 45:1171–1181. [PubMed: 15922782]
- Menchaca JM, Perez JC. The purification and characterization of an antihemorrhagic factor in opossum (*Didelphis virginiana*) serum. *Toxicon*. 1981; 19:623–632. [PubMed: 7302953]
- McKeller MR, Perez JC. The effects of Western Diamondback Rattlesnake (*Crotalus atrox*) venom on the production of antihemorrhagins and/or antibodies in the Virginia opossum (*Didelphis virginiana*). *Toxicon*. 2002; 40:427–439. [PubMed: 11738236]
- Omori-Satoh T, Sadahiro S, Ohsaka A, Murata R. Purification and characterization of an antihemorrhagic factor in the serum of *Trimeresurus flavoviridis*, a crotalid. *Biochim Biophys Acta*. 1972; 285:414–426. [PubMed: 4659650]
- Perales J, Muñoz R, Moussatche H. Isolation and partial characterization of a protein fraction from the opossum (*Didelphis marsupialis*) serum, with protecting property against the *Bothrops jararaca* snake venom. *An Acad Brasil Cienc*. 1986; 58:155–162. [PubMed: 3767145]
- Perales J, Neves-Ferreira AG, Valente RH, Domont GB. Natural inhibitors of snake venom hemorrhagic metalloproteinases. *Toxicon*. 2005; 45:1013–20. [PubMed: 15922772]
- Pérez JC, Haws WC, Garcia VE, Jennings BM 3rd. Resistance of warm-blooded animals to snake venoms. *Toxicon*. 1978; 16:375–383. [PubMed: 684768]
- Perez JC, Pichyangkul S, Garcia VE. The resistance of three species of warm-blooded animals to Western diamondback rattlesnake (*Crotalus atrox*) venom. *Toxicon*. 1979; 17:601–607. [PubMed: 524385]
- Pérez JC, Sánchez EE. Natural protease inhibitors to hemorrhagins in snake venoms and their potential use in medicine. *Toxicon*. 1999; 37:703–728. [PubMed: 10219984]
- Pithayanukul P, Laovachirasuwan S, Bavovada R, Pakmanee N, Suttisri R. Anti-venom potential of butanolic extract of *Eclipta prostrata* against Malayan pit viper venom. *J Ethnopharmacol*. 2004; 90:347–352. [PubMed: 15013200]
- Rodríguez-Acosta A, Aguilar I, Giron ME. Antivenom activity of opossum (*Didelphis marsupialis*) serum fraction. *Toxicon*. 1995; 33:95–98. [PubMed: 7778133]
- Rucavado A, Escalante T, Franceschi A, Chaves F, León G, Cury Y, Ovadia M, Gutiérrez JM. Inhibition of local hemorrhage and dermonecrosis induced by *Bothrops asper* snake venom: effectiveness of early in situ administration of the peptidomimetic metalloproteinase inhibitor batimastat and the chelating agent CaNa2EDTA. *Am J Trop Med Hyg*. 2000; 63:313–319. [PubMed: 11421384]
- Sánchez EE, Garcia C, Perez JC, De La Zerda SJ. The detection of hemorrhagic proteins in snake venoms using monoclonal antibodies against Virginia opossum (*Didelphis virginiana*) serum. *Toxicon*. 1998; 36:1451–1459. [PubMed: 9723843]
- Sánchez EE, Galán JA, Perez JC, Rodriguez-Acosta A, Chase PB, Perez JC. The efficacy of two antivenoms against the venom of North American snakes. *Toxicon*. 2003; 41:357–365. [PubMed: 12565759]
- Spearman-Kärber, R. Alternative methods of analysis for quantal responses. In: Finney, D., editor. *Statistical method in biological assay*. Charles Griffin; London: 1978. p. 1-78.
- Tan NH, Kanthimathi MS, Tan CS. Enzymatic activities of *Calloselasma rhodostoma* (Malayan pit viper) venom. *Toxicon*. 1986; 24:626–630. [PubMed: 3750351]

- Theakston RD, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. *Toxicon*. 2003; 41:541–557. [PubMed: 12676433]
- Viravan C, Looareesuwan S, Kosakarn W, Wuthiekanun V, McCarthy CJ, Stimson AF, Bunnag D, Harinasuta T, Warrell DA. A national hospital-based survey of snakes responsible for bites in Thailand. *Trans R Soc Trop Med Hyg*. 1992; 86:100–106. [PubMed: 1566285]

Fig. 1. Proteolytic activities of *C. rhodostoma* venom and antiproteolytic activity of *D. virginiana* sera. A) fibrinolytic; B) antifibrinolytic; C) hemorrhagic; D) antihemorrhagic; E) gelatinase; F) antigelatinase.

Table 1

Minimal activity doses and lethal dose of Malayan pit viper venom and antiproteolytic activities and effective dose of the *D. virginiana* sera.

Activity	Venom active dose (μg) ¹	Sera active dose (mg) ²	Inhibition ratio ³
MFD	13	0.175	13.5 :1
MHD	15	0.438	29.2 :1
MGD	10	0.022	2.2 :1
LD ₅₀ (mg/kg) ⁴	6.10		
ED ₅₀ (mg/kg) ⁵		546	

¹Venom minimal activity dose: MFD = minimal fibrinolytic dose, the amount of venom protein required to produce a 5 mm clearing zone on a fibrin plate; MHD = minimal hemorrhagic dose, the amount of venom protein required to produce a 10 mm hemorrhagic spot; MGD = minimal gelatinase dose, the amount of venom protein required to produce a 10 mm clearing zone on an X-ray film.

²The amount of opossum sera required to neutralize a minimal activity dose.

³The amount of sera protein in milligrams required to neutralize 1 mg of Malayan pit viper venom.

⁴The amount of venom that will kill 50% of a mouse population.

⁵The amount of sera that will protect 50% of a mouse population injected with 3 LD₅₀ of venom.